BACKGROUND: Severe refractory atopic dermatitis (AD) is a chronic, debilitating condition that is associated with elevated serum immunoglobulin E (IgE) levels. Thymic stromal lymphopoietin (TSLP), thymus and activation-regulated chemokine (TARC) and OX40 ligand (OX40L) are important immunologic factors involved in the pathogenesis of AD. Omalizumab, an anti-IgE antibody indicated for use in allergic asthma, is implicated in regulating allergen presentation by dendritic cells and the T cell response during the effector phases of allergic disease. We investigated if anti-IgE therapy modulates the allergen-specific responses mediated by the TSLP pathway in young patients with severe refractory AD. METHODS: This was a randomized, double-blind, placebo-controlled study of 8 patients between the ages of 4 and 22 years (mean = 11.6 years) with severe refractory AD (clinical trials.gov NCT01678092). Serum IgE ranged from 218 to 1,890 (mean = 1,068 IU/ml). Subjects received omalizumab (n = 4) or placebo (n = 4) every 2-4 weeks over 24 weeks using a regimen extrapolated from the package insert. TSLP, TARC, OX40L and other cytokines involved in AD were measured by using cytometric bead arrays. RESULTS: All patients receiving omalizumab had strikingly decreased levels of TSLP, OX40L, TARC (involved in Th2 polarization) and interleukin (IL)-9 compared to placebo. In addition, there was a marked increase in IL-10, a tolerogenic cytokine, in the omalizumab-treated group. Patients on anti-IgE therapy had an improvement in clinical outcomes as measured by the SCORAD system; however, these effects were comparable to improvements in the control group. CONCLUSIONS: Anti-IgE therapy with omalizumab decreases levels of cytokines that are involved in Th2 polarization and allergic inflammation, including TSLP, TARC and OX40L.
BACKGROUND: Severe refractory atopic dermatitis (AD) is a chronic, debilitating condition that is associated with elevated serum immunoglobulin E (IgE) levels. Thymic stromal lymphopoietin (TSLP), thymus and activation-regulated chemokine (TARC) and OX40 ligand (OX40L) are important immunologic factors involved in the pathogenesis of AD. Omalizumab, an anti-IgE antibody indicated for use in allergic asthma, is implicated in regulating allergen presentation by dendritic cells and the T cell response during the effector phases of allergic disease. We investigated if anti-IgE therapy modulates the allergen-specific responses mediated by the TSLP pathway in young patients with severe refractory AD. METHODS: This was a randomized, double-blind, placebo-controlled study of 8 patients between the ages of 4 and 22 years (mean = 11.6 years) with severe refractory AD (clinical trials.gov NCT01678092). Serum IgE ranged from 218 to 1,890 (mean = 1,068 IU/ml). Subjects received omalizumab (n = 4) or placebo (n = 4) every 2-4 weeks over 24 weeks using a regimen extrapolated from the package insert. TSLP, TARC, OX40L and other cytokines involved in AD were measured by using cytometric bead arrays. RESULTS: All patients receiving omalizumab had strikingly decreased levels of TSLP, OX40L, TARC (involved in Th2 polarization) and interleukin (IL)-9 compared to placebo. In addition, there was a marked increase in IL-10, a tolerogenic cytokine, in the omalizumab-treated group. Patients on anti-IgE therapy had an improvement in clinical outcomes as measured by the SCORAD system; however, these effects were comparable to improvements in the control group. CONCLUSIONS: Anti-IgE therapy with omalizumab decreases levels of cytokines that are involved in Th2 polarization and allergic inflammation, including TSLP, TARC and OX40L.
Authors: Calman Prussin; Daniel T Griffith; Kevin M Boesel; Henry Lin; Barbara Foster; Thomas B Casale Journal: J Allergy Clin Immunol Date: 2003-12 Impact factor: 10.793
Authors: Benedetta Belloni; Mahzad Ziai; Annick Lim; Brigitte Lemercier; Martin Sbornik; Stephan Weidinger; Christian Andres; Christina Schnopp; Johannes Ring; Rüdiger Hein; Markus Ollert; Martin Mempel Journal: J Allergy Clin Immunol Date: 2007-10-22 Impact factor: 10.793
Authors: D W MacGlashan; B S Bochner; D C Adelman; P M Jardieu; A Togias; J McKenzie-White; S A Sterbinsky; R G Hamilton; L M Lichtenstein Journal: J Immunol Date: 1997-02-01 Impact factor: 5.422
Authors: T Kakinuma; K Nakamura; M Wakugawa; H Mitsui; Y Tada; H Saeki; H Torii; A Asahina; N Onai; K Matsushima; K Tamaki Journal: J Allergy Clin Immunol Date: 2001-03 Impact factor: 10.793
Authors: C J Corrigan; A Jayaratnam; Y Wang; Y Liu; R de Waal Malefyt; Q Meng; A B Kay; S Phipps; T H Lee; S Ying Journal: Allergy Date: 2009-02-02 Impact factor: 13.146
Authors: D Bedoret; A K Singh; V Shaw; E G Hoyte; R Hamilton; R H DeKruyff; L C Schneider; K C Nadeau; D T Umetsu Journal: Mucosal Immunol Date: 2012-02-08 Impact factor: 7.313